We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Johnson & Johnson to Supply US Government with 100 Million Doses of Investigational COVID-19 Vaccine

By HospiMedica International staff writers
Posted on 06 Aug 2020
Print article
Image: Johnson & Johnson to Supply US Government with 100 Million Doses of Investigational COVID-19 Vaccine (Photo courtesy of Johnson & Johnson)
Image: Johnson & Johnson to Supply US Government with 100 Million Doses of Investigational COVID-19 Vaccine (Photo courtesy of Johnson & Johnson)
Johnson & Johnson’s (New Brunswick, NJ, USA) Janssen Pharmaceutical Companies have entered into an agreement with the US government for the large scale domestic manufacturing and delivery in the US of 100 million doses of Janssen's SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the US following approval or Emergency Use Authorization by the US Food and Drug Administration (FDA).

The Phase 1/2a first-in-human clinical trial of the vaccine candidate, Ad26.COV2.S, is underway in healthy volunteers in the US and Belgium. The company is evaluating one- and two-dose regimens in its clinical program. Johnson & Johnson's SARS-CoV-2 vaccine program leverages Janssen's AdVac technology which was also used to develop its European Commission-approved Ebola vaccine and construct its HIV, RSV and Zika vaccine candidates. More than 90,000 individuals have been vaccinated to date using the Janssen AdVac-based platform.

Johnson & Johnson's efforts to develop a SARS-CoV-2 vaccine have been undertaken pursuant to an ongoing research and development collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, and under the oversight of the FDA. BARDA, in collaboration with the US Department of Defense, is committing over USD 1 billion for the new agreement. The vaccine will be provided at a global not-for-profit basis for emergency pandemic use. The US government may also purchase an additional 200 million doses of Ad26.COV2.S under a subsequent agreement. Johnson & Johnson is working diligently to ensure broad, global access to the vaccine following approval or authorization by regulators and aims to meet its goal to supply more than one billion doses globally through the course of 2021, provided that the vaccine is safe and effective.

"Johnson & Johnson's global team of experts has worked tirelessly alongside BARDA and scientific partners to pursue a SARS-CoV-2 vaccine that can help to stop the spread of COVID-19. We greatly appreciate the U.S. government's confidence in, and support for, our R&D platform and efforts and the scalability of our vaccine technology. We are scaling up production in the U.S. and worldwide to deliver a SARS-CoV-2 vaccine for emergency use," said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson.

Related Links:
Johnson & Johnson

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
X-Ray Detector
FDR-D-EVO III

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.